MCID: LYM027
MIFTS: 57

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 55 44 15 73
Lymphocytopenia 12 63

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD10 33 D72.810
ICD9CM 35 288.51
MeSH 44 D008231
SNOMED-CT 68 48813009
UMLS 73 C0024312

Summaries for Lymphopenia

PubMed Health : 63 About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites).These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection.Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and thymic dysplasia. An important gene associated with Lymphopenia is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Acetylcysteine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 76 Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 33.7 FOXP3 IFNG RAG1
2 thymic dysplasia 29.9 FOXP3 IL2RG IL7
3 mycosis fungoides 29.8 IL2 IL2RA IL7
4 combined t cell and b cell immunodeficiency 29.7 CD3G IL2 IL2RG IL7 IL7R RAG1
5 autoimmune enteropathy 29.7 FOXP3 IL2RA
6 viral infectious disease 29.6 IFNG IL2 IL7R
7 human immunodeficiency virus infectious disease 29.4 IFNG IL2 IL7
8 cryptococcosis 29.4 IFNG SELL UNC119
9 pancreas adenocarcinoma 29.4 FOXP3 IFNG IL7
10 multiple sclerosis 29.4 FOXP3 IFNG IL2 IL2RA IL7 IL7R
11 autoimmune disease 29.3 FAS FOXP3 IFNG IL2 IL2RA
12 systemic lupus erythematosus 29.3 CD59 FAS FASLG FOXP3 IFNG IL2
13 severe combined immunodeficiency 29.3 IFNG IL2 IL2RG IL7 IL7R RAG1
14 adult t-cell leukemia 29.3 FAS FOXP3 IL2 IL2RA
15 lymphoma, non-hodgkin, familial 29.3 CD59 FAS IL2 IL2RA SELL
16 graft-versus-host disease 29.2 FAS FASLG IFNG IL2
17 human immunodeficiency virus type 1 29.2 IFNG IL2 IL7 LCK
18 pulmonary sarcoidosis 29.2 IFNG IL2 IL2RA
19 leukemia, chronic lymphocytic 29.2 FAS IL2 IL2RA IL7 SELL
20 acquired immunodeficiency syndrome 29.2 IFNG IL2 IL2RA
21 erythema multiforme 29.2 FASLG IFNG IL2
22 visceral leishmaniasis 29.1 FOXP3 IFNG IL2
23 sarcoidosis 1 29.1 IFNG IL2 IL2RA
24 cutaneous t cell lymphoma 29.1 IFNG IL2 IL2RA IL7
25 acute graft versus host disease 29.0 FASLG IFNG IL2 IL2RA
26 omenn syndrome 29.0 FOXP3 IFNG IL2RG IL7R RAG1
27 alopecia areata 29.0 FASLG IFNG IL2 IL2RA
28 dermatitis, atopic 28.8 FOXP3 IFNG IL2 IL2RA SELL
29 diabetes mellitus 28.7 FAS FASLG FOXP3 IFNG IL2 IL2RA
30 malaria 28.6 CD55 FASLG FOXP3 IFNG IL2
31 common variable immunodeficiency 28.4 FAS FOXP3 IFNG IL2 IL2RA LCK
32 immunodeficiency 13 12.0
33 idiopathic cd4-positive t-lymphocytopenia 11.6
34 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection, and neoplasia 11.2
35 immunodeficiency 50 11.1
36 immunodeficiency 14 11.1
37 immunodeficiency 17 11.1
38 sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay 11.1
39 short stature, microcephaly, and endocrine dysfunction 11.1
40 immunodeficiency 52 11.1
41 combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia 11.1
42 severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation 11.1
43 aplasia cutis congenita with intestinal lymphangiectasia 10.9
44 schimke immunoosseous dysplasia 10.9
45 reticular dysgenesis 10.9
46 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 10.9
47 neutropenia, severe congenital, 4, autosomal recessive 10.9
48 immunodeficiency 21 10.9
49 immunodeficiency 8 10.9
50 immunodeficiency 22 10.9

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 CD3G CD55 CD59 FAS FASLG FOXP3
2 endocrine/exocrine gland MP:0005379 10.36 CD3G CD59 FAS FASLG FOXP3 G6PC3
3 immune system MP:0005387 10.3 CD3G CD55 FAS FASLG FOXP3 G6PC3
4 cellular MP:0005384 10.27 CD3G CD59 FAS FASLG FOXP3 IFNG
5 homeostasis/metabolism MP:0005376 10.18 CD59 FAS FASLG FOXP3 G6PC3 IFNG
6 cardiovascular system MP:0005385 10.16 FAS FASLG FOXP3 IFNG IL2 PIK3CD
7 digestive/alimentary MP:0005381 10.13 FAS FASLG FOXP3 IFNG IL2 IL2RA
8 liver/biliary system MP:0005370 9.92 FAS FASLG FOXP3 IFNG IL2 RAG1
9 neoplasm MP:0002006 9.86 FAS FASLG IFNG IL2 IL2RG IL7R
10 normal MP:0002873 9.76 FAS FASLG FOXP3 IFNG IL2RG IL7R
11 respiratory system MP:0005388 9.61 FAS FASLG FOXP3 IFNG IL2 IL2RA
12 vision/eye MP:0005391 9.23 FAS FASLG FOXP3 IFNG IL2 IL2RA

Drugs & Therapeutics for Lymphopenia

PubMedHealth treatment related to Lymphopenia: 63

If you have mild lymphocytopenia with no underlying cause, you may not need treatment. The disorder may improve on its own.If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia, you'll need treatment for the infections.If you have a disease or condition that's causing lymphocytopenia, your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Adenosine Approved, Investigational Phase 4 58-61-7 60961
4
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
6
Ketoconazole Approved, Investigational Phase 4 65277-42-1 3823 47576
7 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Free Radical Scavengers Phase 4
9 Antioxidants Phase 4,Phase 3
10 Respiratory System Agents Phase 4
11 Expectorants Phase 4
12 Protective Agents Phase 4,Phase 3,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 N-monoacetylcystine Phase 4
15 Antidotes Phase 4
16 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
20 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
21 tyrosine Phase 4
22 Steroid Synthesis Inhibitors Phase 4,Phase 2
23 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
24 Proton Pump Inhibitors Phase 4
25 Anti-Ulcer Agents Phase 4
26 Endothelial Growth Factors Phase 4
27 Antifungal Agents Phase 4,Phase 1,Phase 2,Not Applicable
28 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
29 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
30 Antacids Phase 4
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
32 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2
33 gamma-Globulins Phase 4,Phase 3
34 Immunoglobulins, Intravenous Phase 4,Phase 3
35 Rho(D) Immune Globulin Phase 4,Phase 3
36
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
37
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
38
Crizotinib Approved Phase 3,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
40
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
41 tannic acid Approved Phase 3
42
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
43
Ribavirin Approved Phase 3 36791-04-5 37542
44
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
45
Zinc Approved, Investigational Phase 3 7440-66-6
46
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
47
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
48
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
49
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
2 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
3 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
4 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
5 A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung Completed NCT01154140 Phase 3 treatment;treatment
6 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
7 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Completed NCT00387764 Phase 3 pazopanib
8 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
9 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
10 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
11 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Active, not recruiting NCT01774721 Phase 3 Dacomitinib (PF-00299804);Gefitinib
12 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Not yet recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
13 The CRISIS Prevention Study Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
14 Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) Unknown status NCT02772094 Phase 2
15 GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Unknown status NCT00122005 Phase 1, Phase 2
16 Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
17 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
18 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
19 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Completed NCT02640807 Phase 2 Interleukin-7;Placebo
20 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
21 Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00634881 Phase 1, Phase 2
22 A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) Completed NCT00517530 Phase 1, Phase 2 Obinutuzumab
23 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study Completed NCT00630786 Phase 1, Phase 2 Panitumumab;Conatumumab
24 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Completed NCT01471782 Phase 1, Phase 2
25 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
26 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed NCT01008475 Phase 1, Phase 2 EMD 525797 250 mg;EMD 525797 500 mg;EMD 525797 750 mg;EMD 525797 1000 mg;Cetuximab;Irinotecan
27 A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed NCT01357161 Phase 2 MK-1775;Placebo;paclitaxel;carboplatin
28 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
29 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
30 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
31 A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma Completed NCT00942162 Phase 2
32 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed NCT02780167 Phase 2 PF-04965842;PF-04965842;PF-04965842;PF-04965842;Placebo
33 Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients Completed NCT01636778 Phase 2 SB-497115-GR
34 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Completed NCT00284141 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
35 Gene Therapy for WAS Completed NCT01347346 Phase 1, Phase 2
36 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Completed NCT00885833 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
37 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
38 Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia Recruiting NCT03519464 Phase 2
39 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
40 Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). Recruiting NCT03338998 Phase 2 BAF312;Placebo
41 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting NCT02571725 Phase 1, Phase 2 Olaparib;Tremelimumab
42 Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients Recruiting NCT03294486 Phase 1, Phase 2 Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)
43 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant Recruiting NCT03330795 Phase 1, Phase 2
44 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
45 PD 0332991 and Cetuximab in Patients With Incurable SCCHN Recruiting NCT02101034 Phase 1, Phase 2 PD 0332991
46 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
47 Treatment With Tamoxifen in Cryptococcal Meningitis Recruiting NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
48 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
49 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
50 A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Recruiting NCT03019809 Phase 2

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

41
T Cells, Bone, Bone Marrow, B Cells, Breast, Lung, Kidney

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 879)
# Title Authors Year
1
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( 29502931 )
2018
2
Neonatal Alloimmune Thrombocytopenia With Amegakaryocytosis, B Lymphopenia, and Villitis. ( 29610181 )
2018
3
The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. ( 28963724 )
2018
4
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. ( 29143923 )
2018
5
Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. ( 29143922 )
2018
6
A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. ( 29482778 )
2018
7
The Severe Deficiency of the Somatotrope GH-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor 1 Axis of <i>Ghrh<sup>-/-</sup></i> Mice Is Associated With an Important Splenic Atrophy and Relative B Lymphopenia. ( 29928261 )
2018
8
Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs. ( 29526121 )
2018
9
Newborn screening using TREC/KREC assay for severe T and B cell lymphopenia in Iran. ( 29943473 )
2018
10
Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. ( 29027699 )
2018
11
Atrophy of primary lymphoid organs induced by Marek's disease virus during early infection is associated with increased apoptosis, inhibition of cell proliferation and a severe B-lymphopenia. ( 29587836 )
2018
12
Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. ( 29497558 )
2018
13
Erratum: Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29417951 )
2018
14
Calorie restriction induces reversible lymphopenia and lymphoid organ atrophy due to cell redistribution. ( 29804201 )
2018
15
Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia. ( 29725107 )
2018
16
Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. ( 29512868 )
2018
17
A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. ( 28961694 )
2018
18
Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. ( 29948248 )
2018
19
Severe Lymphopenia and Related T-cell Immunity in an Avian Influenza A (H7N9)-Infected Patient. ( 30425209 )
2018
20
The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. ( 30247248 )
2018
21
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. ( 30227312 )
2018
22
Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer. ( 30348711 )
2018
23
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. ( 29248170 )
2018
24
Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia. ( 30327760 )
2018
25
Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia. ( 29643659 )
2018
26
Idiopathic CD4 lymphocytopenia presenting with progressive disseminated histoplasmosis. ( 30093774 )
2018
27
Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study. ( 28387829 )
2018
28
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29296636 )
2018
29
Lymphopenia-induced proliferation of CD4 T-cells is associated with CD4 T-lymphocyte exhaustion in treated HIV-infected patients. ( 29998873 )
2018
30
Respiratory signs, fever and lymphopenia in calves inoculated with Brazilian HoBi-like pestiviruses. ( 30040999 )
2018
31
Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer. ( 30095290 )
2018
32
Endogenous co-expression of two T cell receptors promotes lymphopenia-induced proliferation via increased affinity for self-antigen. ( 30168881 )
2018
33
Opinion: Virtual memory CD8 T cells and lymphopenia-induced memory CD8 T cells represent a single subset: Homeostatic memory T cells. ( 30243945 )
2018
34
Postoperative lymphopenia: An independent risk factor for postoperative pneumonia after lung cancer surgery, results of a case-control study. ( 30321194 )
2018
35
Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. ( 30370350 )
2018
36
Consider Syphilis in Case of Lymphopenia in HIV-Infected Men Who Have Sex with Men (MSM): A Single-center, Retrospective Study. ( 30377976 )
2018
37
Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. ( 30383787 )
2018
38
Cerebral toxoplasmosis in a patient with prolonged CD4 lymphopenia post autologous hemopoietic stem cell transplant. ( 30407076 )
2018
39
Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. ( 30409288 )
2018
40
Plateletpheresis-associated lymphopenia in frequent platelet donors. ( 30429159 )
2018
41
Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer. ( 30506281 )
2018
42
Cryptococcal-related meningoencephalitis in a patient with sarcoidosis and CD4 lymphocytopenia: thorough immunological characterization of lymphocyte homeostasis. ( 29480693 )
2018
43
Isolated renal mucormycosis in a patient with Idiopathic CD4 lymphocytopenia. ( 30413437 )
2018
44
Pulmonary nocardiosis in a patient with idiopathic CD4 T-lymphocytopenia. ( 29321927 )
2018
45
Idiopathic CD4 Lymphocytopenia with Fulminant Pneumocystis Jiroveci Pneumonia. ( 30321488 )
2018
46
Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. ( 29987583 )
2018
47
Interferon-stimulated gene 15 expression in systemic lupus erythematosus : Diagnostic value and association with lymphocytopenia. ( 28204879 )
2018
48
Pneumocystis Pneumonia Secondary to Idiopathic CD4+ T-lymphocytopenia: A Comparison of AIDS and Non-AIDS Patients. ( 29093385 )
2018
49
Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis. ( 29532704 )
2018
50
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? ( 28512628 )
2017

Variations for Lymphopenia

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CD3G CD55 CD59 FASLG IFNG IL2
2
Show member pathways
13.69 CD3G FAS FASLG IFNG IL2 IL2RA
3
Show member pathways
13.46 CD3G FAS FASLG IL2 IL2RA IL2RG
4
Show member pathways
13.41 FASLG IFNG IL2 IL2RA IL2RG IL7
5
Show member pathways
13.31 FAS FASLG IL2 IL2RA IL2RG IL7
6
Show member pathways
13.02 CD3G FAS FASLG IFNG IL2 PIK3CD
7
Show member pathways
13 FAS FASLG G6PC3 IL2 IL2RA IL2RG
8
Show member pathways
12.87 CD3G CD55 FAS FASLG FOXP3 IFNG
9
Show member pathways
12.83 IL2 IL2RA IL2RG IL7 IL7R PIK3CD
10
Show member pathways
12.81 CD3G FAS FASLG IFNG IL2 IL2RA
11 12.81 FAS FASLG IFNG IL2 IL2RA IL2RG
12
Show member pathways
12.7 CD3G IFNG IL2 IL2RA LCK PIK3CD
13
Show member pathways
12.65 CD3G FOXP3 IFNG IL2 IL2RA IL2RG
14
Show member pathways
12.6 FAS FASLG IFNG IL2 LCK PIK3CD
15 12.52 FAS FASLG FOXP3 IFNG IL2 IL2RA
16
Show member pathways
12.51 CD3G FAS IFNG IL2 LCK PIK3CD
17 12.5 CD3G IL2 IL2RA IL2RG LCK PIK3CD
18
Show member pathways
12.45 CD3G IL2 IL2RA IL2RG LCK
19
Show member pathways
12.29 IFNG IL2 IL2RA IL2RG IL7 IL7R
20
Show member pathways
12.24 IL2 IL2RA IL2RG LCK PIK3CD
21
Show member pathways
12.18 FASLG G6PC3 IL7R PIK3CD RAG1
22
Show member pathways
12.17 IFNG IL2 IL2RA IL2RG LCK
23
Show member pathways
12.14 CD3G IL2 LCK PIK3CD
24
Show member pathways
12.14 IFNG IL2 IL2RA IL2RG IL7 IL7R
25
Show member pathways
12.06 IL2 IL2RA IL2RG LCK PIK3CD
26
Show member pathways
11.97 IL2 IL2RA PIK3CD
27 11.97 IFNG IL2 IL2RA IL7R LCK
28 11.92 CD3G CD55 CD59 IL2RA IL7 IL7R
29 11.86 IFNG IL2 IL2RA IL7 IL7R
30 11.84 IFNG IL2 IL7R SELL
31
Show member pathways
11.83 FASLG FOXP3 IFNG IL2 IL2RA
32 11.74 FAS FASLG PIK3CD
33 11.66 FAS FASLG IFNG IL2
34
Show member pathways
11.6 IL2RA IL2RG IL7 IL7R
35 11.56 FOXP3 IFNG IL2 IL2RA IL2RG
36
Show member pathways
11.56 FASLG FOXP3 IL2 IL2RA IL2RG LCK
37 11.56 CD59 IFNG IL2 IL2RA IL7 IL7R
38 11.53 IL2RA IL7R LCK
39 11.48 IL2RG IL7R LCK RAG1
40
Show member pathways
11.42 CD3G FASLG IFNG IL2 IL2RA IL2RG
41 11.4 FAS FASLG IFNG
42 11.35 CD3G IFNG IL2 IL2RA
43 11.34 IL2RG IL7 IL7R RAG1
44 11.32 IFNG IL2 IL7
45
Show member pathways
11.3 IL2 IL2RA IL2RG LCK PIK3CD
46 11.28 IFNG IL2 IL2RA IL2RG LCK
47
Show member pathways
11.22 CD3G FASLG IFNG IL2 IL2RA IL2RG

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 CD55 FAS FASLG LCK
2 cell surface GO:0009986 9.43 CD55 CD59 FAS FASLG IL2RA SELL
3 external side of plasma membrane GO:0009897 9.1 CD3G FASLG IL2RA IL2RG IL7R SELL
4 plasma membrane GO:0005886 10.03 CD3G CD55 CD59 FAS FASLG IL2RA

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.89 CD3G IFNG IL2 PIK3CD RAG1
2 cell surface receptor signaling pathway GO:0007166 9.85 CD3G CD59 IFNG IL2RA IL7R
3 T cell receptor signaling pathway GO:0050852 9.81 CD3G FOXP3 LCK PIK3CD
4 negative regulation of inflammatory response GO:0050728 9.8 FOXP3 IL2 IL2RA
5 cytokine-mediated signaling pathway GO:0019221 9.8 FASLG IL2 IL2RA IL2RG IL7 IL7R
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 FAS FASLG LCK
7 T cell activation GO:0042110 9.72 CD3G FOXP3 PIK3CD
8 extrinsic apoptotic signaling pathway GO:0097191 9.71 FAS FASLG IFNG
9 interleukin-7-mediated signaling pathway GO:0038111 9.65 IL2RG IL7 IL7R
10 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.63 FAS FASLG
11 positive regulation of T cell differentiation GO:0045582 9.62 IL2 IL2RA IL7 RAG1
12 negative regulation of immune response GO:0050777 9.61 FOXP3 IL2RA
13 T cell homeostasis GO:0043029 9.61 FOXP3 IL2RA RAG1
14 negative regulation of interleukin-17 production GO:0032700 9.59 FOXP3 IFNG
15 positive regulation of regulatory T cell differentiation GO:0045591 9.58 FOXP3 IL2
16 negative regulation of T cell apoptotic process GO:0070233 9.58 IL7R RAG1
17 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2 IL2RA IL2RG
18 negative regulation of T-helper 17 cell differentiation GO:2000320 9.57 FOXP3 IL2
19 necroptotic signaling pathway GO:0097527 9.56 FAS FASLG
20 negative regulation of lymphocyte proliferation GO:0050672 9.54 FOXP3 IL2 IL2RA
21 regulation of T cell homeostatic proliferation GO:0046013 9.52 IL2 IL2RA
22 regulation of regulatory T cell differentiation GO:0045589 9.46 FOXP3 IFNG IL2 IL2RA
23 T cell differentiation GO:0030217 9.35 CD3G IL2 IL7R LCK PIK3CD
24 immune response GO:0006955 9.28 FAS FASLG IFNG IL2 IL2RA IL2RG
25 immune system process GO:0002376 10.02 CD3G CD55 IL2 IL2RA PIK3CD
26 positive regulation of cell proliferation GO:0008284 10 FASLG IFNG IL2 IL7 IL7R

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 FASLG IFNG IL2 IL7
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 IL2 IL2RA IL2RG
3 T cell receptor binding GO:0042608 9.32 CD3G LCK
4 glycosphingolipid binding GO:0043208 9.26 IL2 SELL
5 interleukin-2 binding GO:0019976 9.16 IL2RA IL2RG
6 interleukin-2 receptor activity GO:0004911 8.96 IL2RA IL2RG
7 interleukin-7 receptor activity GO:0004917 8.62 IL2RG IL7R
8 protein binding GO:0005515 10.31 CD55 CD59 FAS FASLG FOXP3 IFNG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....